The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy

被引:77
|
作者
Gulcebi, Medine Idrizoglu [1 ]
Ozkaynakci, Aydan [1 ]
Goren, Mehmet Zafer [1 ]
Aker, Rezzan Gulhan [1 ]
Ozkara, Cigdem [2 ]
Onat, Filiz Yilmaz [1 ]
机构
[1] Marmara Univ, Sch Med, Dept Pharmacol, TR-34668 Istanbul, Turkey
[2] Istanbul Univ, Dept Neurol, Cerrahpasa Med Fac, Istanbul, Turkey
关键词
Lamotrigine; Genetic polymorphism; Glucuronidation; Pharmacogenomics; Pharmacotherapy; ANTIEPILEPTIC DRUGS; GLUCURONIDATION; PHARMACOKINETICS; PREGNANCY; POPULATION; PLASMA;
D O I
10.1016/j.eplepsyres.2011.01.016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Lamotrigine (LTG) which has a widespread use in epilepsy treatment as an antiepileptic agent is metabolized by UDP-glucuronosyl transferase (UGT) enzymes. In this study, single nucleotide polymorphisms, P24T and L48V, of the UGT1A4 enzyme have been investigated in a Turkish population of patients with epilepsy (n=131) by comparing serum levels of LTG of wild type and polymorphic subjects. High performance liquid chromatography (HPLC) was used to measure serum concentrations of LTG. The P24T and L48V polymorphisms of the UGT1A4 enzyme were analyzed with a matrix assisted laser desorption-time of flight (MALDI-TOF) mass spectrometry method. The frequencies of the heterozygous alleles for L48V or P24T polymorphisms were 22.4% and 3.8%, respectively. L48V polymorphism was found to decrease the serum concentration of LTG in patients on monotherapy or polytherapy. The LTG levels of non smoking monotherapy patients were 52% lower for the L48V polymorphism than for wild type alleles. Also the LTG levels were significantly lower for non smoking or smoking polymorphic alleles than for normal. The high frequency of the L48V polymorphism detected in the Turkish population indicates that LTG dose adjustments in patients with the UGT1A4 L48V polymorphic enzyme should be taken into account. (c) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [31] Pediatric development of glucuronidation: The ontogeny of hepatic UGT1A4
    Miyagi, Shogo J.
    Collier, Abby C.
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (09) : 1587 - 1592
  • [32] The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension
    Suh, Hyeon Jeong
    Yoon, Seo Hyun
    Yu, Kyung-Sang
    Cho, Joo-Youn
    Park, Sang-In
    Lee, Eunyoung
    Lee, Jeong-Ok
    Koh, Youngil
    Song, Kyoung-Ho
    Choe, Pyoeng Gyun
    Kim, Eu Suk
    Bang, Soo-Mee
    Kim, Hong Bin
    Kim, Inho
    Kim, Nam Joong
    Song, Sang Hoon
    Park, Wan Beom
    Oh, Myoung-don
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (07)
  • [33] Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations
    Lopez, Marisol
    Dorado, Pedro
    Ortega, Alberto
    Penas-Lledo, Eva
    Monroy, Nancy
    Silva-Zolezzi, Irma
    Cobaleda, Jesus
    Gallego-Aguilera, Alicia
    Elisa Alonso, Maria
    LLerena, Adrian
    MOLECULAR BIOLOGY REPORTS, 2013, 40 (04) : 3187 - 3192
  • [34] Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations
    Marisol López
    Pedro Dorado
    Alberto Ortega
    Eva Peñas-Lledó
    Nancy Monroy
    Irma Silva-Zolezzi
    Jesús Cobaleda
    Alicia Gallego-Aguilera
    María Elisa Alonso
    Adrián LLerena
    Molecular Biology Reports, 2013, 40 : 3187 - 3192
  • [35] Axitinib N-glucuronidation is primarily mediated by UGT1A1 versus UGT1A4
    Goosen, Theunis C.
    Lin, Jian
    Lapham, Kimberly
    Niosi, Mark
    Orozco, Christine C.
    Tseng, Elaine
    Bauman, Jonathan N.
    Walker, Gregory S.
    Kang, Ping
    Jiang, Ying
    Freiwald, Sascha
    Neul, David
    Smith, Bill J.
    Zientek, Michael A.
    DRUG METABOLISM REVIEWS, 2016, 48 : 36 - 36
  • [36] Effect of lamotrigine on carbamazepine epoxide carbamazepine serum concentration ratios in adult patients with epilepsy
    Gidal, BE
    Rutecki, P
    Shaw, R
    Maly, MM
    Collins, DM
    Pitterle, ME
    EPILEPSY RESEARCH, 1997, 28 (03) : 207 - 211
  • [37] Potential Role of UGT1A4 Promoter SNPs in Anastrozole Pharmacogenomics
    Edavana, Vineetha Koroth
    Dhakal, Ishwori B.
    Williams, Suzanne
    Penney, Rosalind
    Boysen, Gunnar
    Yao-Borengasser, Aiwei
    Kadlubar, Susan
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (04) : 870 - 877
  • [38] Midazolam is metabolized by UGT1A4 in human hepatocytts and hepatic microsomes
    Siddle, DW
    Faithfull, L
    Gleave, M
    Wright, P
    Lindsay, N
    Kohl, C
    DRUG METABOLISM REVIEWS, 2003, 35 : 55 - 55
  • [39] UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population
    Hakooz, Nancy
    Alzubiedi, Sameh
    Yousef, Al-Motassem
    Arafat, Tawfiq
    Dajani, Rana
    Ababneh, Nidaa
    Ismail, Said
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (07) : 7763 - 7768
  • [40] Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants
    Dongxiao Sun
    Gang Chen
    Ryan W Dellinger
    Kimberly Duncan
    Jia-Long Fang
    Philip Lazarus
    Breast Cancer Research, 8